The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort

Basit Öğe Kaydı
dc.authoridFakılı, Füsun/0000-0002-1602-5240
dc.authoridKetencioğlu, Burcu Baran/0000-0002-6757-3140
dc.authoridEyüboğlu, Füsun/0000-0002-5525-8207
dc.authoridergan, begum/0000-0003-2920-9214
dc.authoridGemicioglu, Bilun/0000-0001-5953-4881
dc.authoridBAYDAR TOPRAK, OYA/0000-0001-7320-976X
dc.authoridElbek, Osman/0000-0002-8968-2436
dc.authorwosidFakılı, Füsun/ABV-9256-2022
dc.authorwosidKetencioğlu, Burcu Baran/AAO-9889-2021
dc.authorwosidergan, begum/U-8276-2017
dc.authorwosidEyüboğlu, Füsun/AAR-4338-2020
dc.authorwosidGemicioglu, Bilun/AAH-6927-2019
dc.authorwosidBAYDAR TOPRAK, OYA/U-9880-2018
dc.authorwosidElbek, Osman/HKV-4982-2023
dc.contributor.authorBabayiğit, Cenk
dc.contributor.authorKöktürk, Nurdan
dc.contributor.authorKul, Seval
dc.contributor.authorÇetinkaya, Pelin Duru
dc.contributor.authorNayci, Sibel Atis
dc.contributor.authorArgun Barış, Serap
dc.contributor.authorKarcıoğlu, Oğuz
dc.date.accessioned2023-07-26T11:50:46Z
dc.date.available2023-07-26T11:50:46Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Göğüs Hastalıkları Anabilim Dalıen_US
dc.description.abstractBackground and objectivesAlthough several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. MethodsPatients admitted to 26 different hospitals located in 16 different provinces between March 11-July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. ResultsWe retrospectively evaluated 1,472 COVID-19 adult patients; 57.1% were men (mean age = 51.9 +/- 17.7years). A total of 210 (14.3%) had severe pneumonia, 115 (7.8%) were admitted to ICUs, and 69 (4.7%) were intubated during hospitalization. The median (interquartile range) of duration of hospitalization, including ICU admission, was 7 (5-12) days. Favipiravir (n = 328), lopinavir/ritonavir (n = 55), and oseltamivir (n = 761) were administered as antiviral agents, and hydroxychloroquine (HCQ, n = 1,382) and azithromycin (n = 738) were used for their immunomodulatory activity. Lopinavir/ritonavir (beta [95% CI]: 4.71 [2.31-7.11]; p = 0.001), favipiravir (beta [95% CI]: 3.55 [2.56-4.55]; p = 0.001) and HCQ (beta [95% CI]: 0.84 [0.02-1.67]; p = 0.046) were associated with increased risk of lengthy hospital stays. Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70-5.35]; p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28-6.75]; p = 0.011). ConclusionOur findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment.en_US
dc.identifier.doi10.3389/fmed.2022.894126
dc.identifier.issn2296-858X
dc.identifier.pmid36117966en_US
dc.identifier.scopus2-s2.0-85138400187en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3389/fmed.2022.894126
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12424
dc.identifier.volume9en_US
dc.identifier.wosWOS:000877589000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorErçelik, Merve
dc.institutionauthorAtaoğlu, Özlem
dc.language.isoenen_US
dc.publisherFrontiers Media Saen_US
dc.relation.ispartofFrontiers In Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectAntiviral Agents; Covid-19 Morbidity; Length Of Hospitalization; Icu Requirement; Invasive Mechanical Ventilationen_US
dc.subjectIcu Admission Rates; Favipiravir; Hydroxychloroquine; Collegeen_US
dc.titleThe association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohorten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12424.pdf
Boyut:
1.27 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu